Navigation Links
Tumor-Targeted Rexin-G Prolongs Survival in Gemcitabine-Resistant Metastatic Pancreas Cancer in Advanced Phase I and II Studies (ASCO 2010)
Date:5/24/2010

SAN MARINO, Calif., May 24 /PRNewswire/ -- Epeius Biotechnologies Corporation (www.epeiusbiotech.com) today announces the results of the clinical study entitled "Phase I and II Studies of Intravenous Rexin-G as Monotherapy for Gemcitabine-resistant Metastatic Pancreas Cancer" at the ASCO Annual Meeting on June 6, 2010. The presentation will be discussed by Dr. Howard W. Bruckner, Bruckner Oncology, New York, NY.

STUDY SUMMARY: The goals of the Phase I/II study were to evaluate the overall safety and efficacy of intravenous infusions of Rexin-G, a tumor-targeted retrovector bearing a cytocidal anti-cyclin G1 construct, in gemcitabine-resistant pancreas cancer. A Phase II "run in" study was integrated by adaptive design wherein additional cycles were given if the patient had Grade 1 or less toxicity. Twenty patients received escalating doses of Rexin-G intravenously three times a week for four weeks. Analysis of safety showed no dose-limiting toxicity and no cumulative toxicity in patients treated up to 18 months. Analysis of efficacy in evaluable patients revealed significant tumor responses:  100% tumor control rate (TCR) was observed at all doses tested, and 24% partial response (PR) or complete response (CR) by RECIST criteria in the high dose cohorts. A dose-dependent relationship between overall survival and Rexin-G dosage was demonstrated, which was significant at the 5% statistical level by log rank test (p = 0.03). Median survival was 9.3 months and one-year survival was 33% in the high dose groups. Remarkably, one patient exhibited a complete response with the (adaptive) repeated cycles, attaining clinical remission after 9 months of continued treatment with Rexin-G. These findings indicate that intravenous Rexin-G is safe and well-tolerated with no cumulative toxicity and that Rexin-G controls tumor growth and may prolong over-all survival in a dose-dependent manner in patients with gemcitabine-resistant pancreas cancer.                          

About Epeius Biotechnologies:

Epeius Biotechnologies Corporation (www.epeiusbiotech.com) is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its lead products, Rexin-G and Reximmune-C, and its high-performance gene delivery systems. To learn more about these agents and/or ongoing clinical trials, please contact Dr. Erlinda M. Gordon at egordon@epeiusbiotech.com.  

*(LOGO 72dpi: www.send2press.com/mediaboom/10-0504-epeiusbio_72dpi.jpg)

This release was issued on behalf of the above organization by Send2Press(R), a unit of Neotrope(R). http://www.Send2Press.com


'/>"/>
SOURCE Epeius Biotechnologies
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. ASCO 2008: Tumor-Targeted Rexin-G Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Metastatic Pancreatic Cancer
2. Epeius Biotechnologies Tumor-Targeted Rexin-G Receives FDA Orphan Drug Designation for the Treatment of Osteosarcoma
3. Tumor-Targeted Nanoparticle-based Gene Delivery Provides Evidence of Therapeutic Vaccination in Patients with Metastatic Cancer (ASCO 2010)
4. FDA Grants Epeius Biotechnologies Rexin-G a Third Orphan Drug Designation, This Time for the Treatment of Soft Tissue Sarcomas
5. Epeius Biotechnologies Lead Product, Rexin-G for Metastatic Cancer, Aptly Highlighted by National Cancer Institute Journal
6. Rexin-G Returns to The Big Apple: Clinical Trials for Pancreatic Cancer and Breast Cancer Open in Manhattan
7. REXIN-G Shrinks Metastatic Tumors and Triples Survival Time in Chemotherapy-Resistant Pancreatic Cancer: Analysis of a U.S. Phase I/II Clinical Trial (Proceedings of ASCO GI Symposium 2009)
8. Beginners Luck, or Creative Artists of the First Rank? Epeius Biotechnologies Launches Rexin-G eBook Tutorial
9. The Worlds Smallest Hero! Rexin-G, Targeted Therapy for Metastatic Cancers
10. Epeius Biotechnologies Corporation Expands its Rexin-G Production Facilities in Southern California
11. PROVENGE Significantly Prolongs Survival in Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2016)... CA (PRWEB) , ... May 20, 2016 , ... The ... 10 of its most experienced veterinary clients have treated over 100 of their own ... edge technology to provide the highest level of care for their patients. , ...
(Date:5/19/2016)... MAPLE RIDGE, British Columbia , May 19, ... of AdvanTec Global Innovations Inc. (AGI), based out ... recently added Greenlane Biogas Ltd. to its ... a 2-year contract manufacturing agreement. AFS along with ... Bending Technologies (ABT) is a vertically integrated industrial ...
(Date:5/18/2016)... Irvine, Calif. (PRWEB) , ... May 18, 2016 , ... ... had awarded the Luis Villalobos Award to Cognition Therapeutics at the annual ACA Summit ... innovative company that is financed by one of ACA’s member angel groups. It is ...
(Date:5/18/2016)... ... May 18, 2016 , ... The Academy of Model Aeronautics has ... dream of reaching a total of $1 million in awarded scholarships. , The AMA ... school graduates from across the nation has helped bring the total of AMA scholarships ...
Breaking Biology Technology:
(Date:3/18/2016)... --> --> Competitive Landscape ... Vehicles, Physical infrastructure and Perimeter Surveillance & Detection Systems ... market and the continuing migration crisis in the ... has led visiongain to publish this unique report, which is ... & security companies in the border security market and ...
(Date:3/14/2016)... http://www.apimages.com ) - ... - Renvoi : image disponible via AP Images ( ... --> DERMALOG, le leader de l,innovation ... d,empreintes digitales pour l,enregistrement des réfugiés en Allemagne. ... produire des cartes d,identité aux réfugiés. DERMALOG dévoilera ...
(Date:3/9/2016)... , March 9, 2016 This BCC Research ... states of the RNA Sequencing (RNA Seq) market for ... as instruments, tools and reagents, data analysis, and services. ... segments of the RNA-Sequencing market such as RNA-Sequencing tools ... the main factors affecting each segment and forecast their ...
Breaking Biology News(10 mins):